Famed investor Bill Miller is still a believer in Facebook. "This too will pass," he said in an email to CNBC's Scott Wapner.
Keep Reading →
March 21 - Hedge Funds, Insider Trading
President Donald Trump in his inaugural speech to a joint session of Congress characterized the approval process of drugs at the U.S.
Keep Reading →
March 2 - News, Stock Analysis
Amicus Therapeutics, Inc.
Keep Reading →
December 22 - News, Stock Analysis
Amicus Therapeutics, Inc. (NASDAQ:FOLD) just announced a convertible senior notes offering, and the company is trending down on he back of the news.
Keep Reading →
December 15 - News, Stock Analysis
Hedge funds run by legendary names like Nelson Peltz and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to...
Keep Reading →
December 7 - Hedge Funds, News
It’s time to take a look at those stocks that really moved over the last twenty-four hours or so in biotech, and there are plenty to go at.
Keep Reading →
November 29 - Market Movers, News, Stock Analysis
Despite of all the negative sentiment looming around them, hedge funds had a pretty solid run for much of this year, generating positive returns for seven or eight consecutive...
Keep Reading →
November 15 - Hedge Funds, News
While wider markets turn there focus to the US elections, the biotech space is alive and well, and after a tough end to last week, a number of companies have enjoyed gains throughout...
Keep Reading →
November 8 - Market Movers, News
Joseph Edelman's Perceptive Advisors is a fund that has an equity portfolio worth $1.44 billion as of the end of June, with over 80% of it being invested in healthcare stocks.
Keep Reading →
November 8 - Hedge Funds, News
The healthcare sector has witnessed a significant correction in the last 15 months, with many prominent names in the industry losing a noteworthy chunk of their market capitalization...
Keep Reading →
October 8 - Hedge Funds, News
Redmile Group is a San Francisco-based, healthcare-focused hedge fund founded and managed by Jeremy Green, an Oxford alum with more than 20 years of experience in wealth management...
Keep Reading →
June 3 - Hedge Fund Analysis, Hedge Funds, News
Amicus Therapeutics, Inc. (NASDAQ:FOLD)'s lead drug candidate is migalastat, which targets Fabry disease.
Keep Reading →
May 21 - News
The markets are going nowhere today, after the IMF cut its global growth forecast for the fourth time over the past twelve months, due to China's slowdown.
Keep Reading →
April 12 - Market Movers, News
Oil went back to tumbling on Friday, with crude oil losing more than 3.5%. On the other hand, markets returned to positive territory, with major U.S.
Keep Reading →
April 1 - Market Movers, News
Bloomberg recently came out with its list of best performing hedge funds of 2015 and the fund that managed to beat all its rivals and emerge at the top of the list was biotech...
Keep Reading →
February 27 - Hedge Funds, News
Redmile Group is a San Francisco-based investment firm managed by Jeremy Green, which primarily focuses on the healthcare sector.
Keep Reading →
February 26 - Hedge Funds, News
Over the past few months the healthcare sector has undergone a roller coaster of a ride, especially in August and September when many investors got wary of the sector being overvalued...
Keep Reading →
December 20 - Hedge Funds, News
Given elite hedge funds have filed their latest 13F's, we have an opportunity to analyze what hedge funds like and what they don't like.
Keep Reading →
December 11 - Hedge Funds, News
The third-quarter stock market correction has turned out to resemble the situation observed during the Asian financial crisis of 1997.
Keep Reading →
November 25 - Hedge Funds, News
Shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Novavax, Inc.
Keep Reading →
November 2 - Market Movers, News
It’s a good Monday for investors of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV), Amicus Therapeutics, Inc. (NASDAQ:FOLD), and Oasis Petroleum Inc.
Keep Reading →
October 5 - Market Movers, News
Three stocks trending significantly low today before afternoon were Amicus Therapeutics, Inc.
Keep Reading →
October 2 - Market Movers, News
Biotech Guru Joseph Edelman's Perceptive Advisors is known for its long-short investment approach that focuses on biotech stocks.
Keep Reading →
June 25 - Hedge Funds, News
Ken Griffin's Citadel Investment Group has increased its stakes in Tuesday Morning Corporation (NASDAQ:TUES), Swift Transportation Co (NYSE:SWFT), and Amicus Therapeutics, Inc...
Keep Reading →
April 28 - Hedge Funds, News
Jeremy Green's Redmile Group has also reduced its stake in Amicus Therapeutics, Inc.
Keep Reading →
October 9 - Hedge Funds, News
William Leland Edwards’ Palo Alto Investors disclosed today a 50% decrease in its exposure to Amicus Therapeutics, Inc. (NASDAQ:FOLD).
Keep Reading →
October 8 - Hedge Funds, News
Perceptive Advisors, managed by Joseph Edelman, is bullish on Amicus Therapeutics Inc. (NASDAQ:FOLD). In a new filing with the U.S.
Keep Reading →
July 2 - Hedge Funds, News
Jeremy Green's Redmile Group has significantly surged its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD), a new filing with the SEC revealed.
Keep Reading →
November 29 - Hedge Funds, News
At the moment, there are many indicators market participants can use to watch their holdings. Two of the most under-the-radar are hedge fund and insider trading activity.
Keep Reading →
September 17 - News
Now, according to many investors, hedge funds are assumed to be overrated, outdated investment tools of an era lost to time.
Keep Reading →
September 17 - News
In the eyes of many investors, hedge funds are viewed as overrated, old investment vehicles of an era lost to time.
Keep Reading →
September 6 - News
In the eyes of most stock holders, hedge funds are seen as underperforming, outdated financial vehicles of years past.
Keep Reading →
June 26 - News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) was in 12 hedge funds' portfolio at the end of March.
Keep Reading →
June 14 - News
BioDelivery Sciences International, Inc.
Keep Reading →
June 13 - News
Is Pain Therapeutics, Inc. (NASDAQ:PTIE) a buy, sell, or hold? The smart money is in a bearish mood.
Keep Reading →
June 10 - News
Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) a marvelous investment today? Money managers are becoming less confident.
Keep Reading →
April 13 - News
Horse meat and Wal-Mart Stores, Inc.
Keep Reading →
February 20 - News
With the SPDR S&P Biotech Index up 20% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
February 18 - News
The Ides of March meant bad news for Julius Caesar. Similarly, the week surrounding the Ides of February haven't turned out so well for several health-care stocks.
Keep Reading →
February 16 - News
Buckeye Partners, L.P. (NYSE:BPL) recently announced plans to issue additional limited partnership units. Citigroup Inc.
Keep Reading →
February 5 - News
